COGNITION AND BEHAVIOR IN DOWN SYNDROME Release Date: March 27, 1998 RFA: HD-98-007 P.T. National Institute of Child Health and Human Development National Institute of Neurological Disorders and Stroke Letter of Intent Receipt Date: May 1, 1998 Application Receipt Date: June 11, 1998 PURPOSE The Mental Retardation and Developmental Disabilities Branch (MRDD), Center for Research for Mothers and Children (CRMC), of the National Institute of Child Health and Human Development (NICHD), and the Division of Fundamental Neuroscience and Developmental Disorders (DFNDD) of the National Institute of Neurological Disorders and Stroke (NINDS), in collaboration with the National Down Syndrome Society (NDSS), invite research grant applications that address various aspects of cognition and behavior in individuals with Down Syndrome (DS). Areas of interest include the developmental and neurological mechanisms underlying characteristic loss of function, approaches toward preserving or improving level of function, and methods to assess effects of interventions. Six to seven awards may be funded under this grant solicitation subject to the availability of funds. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Cognition and Behavior in Down Syndrome, is related to the priority areas on chronic disabling conditions, nutrition, and educational and community-based programs. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, and units of state or local governments, and eligible agencies of the Federal government. Applicants may collaborate, through consultation or contractual arrangements, with foreign investigators. Applications from minority individuals, women and persons with disabilities are encouraged. MECHANISM OF SUPPORT This RFA will use the NIH research project (R01) and small research grants (R03) (NICHD only) mechanisms. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. The total project period for an application submitted in response to this RFA may not exceed five years. For R03s, the total project period may not exceed two years. The anticipated date of award is September 30, 1998. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and will be reviewed according to the customary NIH peer review procedures. FUNDS AVAILABLE Research grant applications submitted in response to this RFA will compete for $1.3 million in total costs that will be made available for the first year of support. Through a partnership agreement, the NDSS in New York will contribute $200,000 and NICHD $800,000. NINDS will contribute $300,000. It is anticipated that six to seven awards will be made. The number of awards depends on the overall scientific merit of the applications and the availability of funds in fiscal year 1998. RESEARCH OBJECTIVES Background The MRDD Branch, NICHD supports research that relates to the biological, behavioral and social processes that contribute to, or influence the development of mental retardation and developmental disabilities. Prevention of mental retardation and developmental disabilities, and amelioration of the clinical manifestations of those afflicted constitute areas of special emphasis within the MRDD Branch. DFNDD, NINDS supports research on developmental neurological disorders. The mechanisms underlying inherited neurological disorders are of particular interest. Genetic disorders have become increasingly prominent in the etiology of mental retardation. With aggressive use of antimicrobial agents to treat infectious diseases, widespread immunization programs to protect against bacterial and viral infectious agents, better nutrition, and surgical correction of congenital abnormalities, those with genetic disorders, many of them with mental retardation, who otherwise would have succumbed are able to survive longer. Trisomy is the most commonly recognized chromosome abnormality in humans, occurring in at least 4% of all clinically recognized pregnancies. Some trisomies are compatible with postnatal life; however, most trisomic fetuses do not survive to term. They are associated either with clinically recognized spontaneous abortions, where they account for approximately 25% of all such fetuses, or they terminate as subclinical spontaneous abortions. DS is the most common genetic cause of mental retardation, affecting 1 in 800 live-born infants, and is due to triplication of a portion of the long arm of chromosome 21 (2lq22). In addition to mental retardation, the following associated defects have been described in children with DS: congenital heart defects, duodenal stenosis or atresia, keratoconus, astigmatism, and myopia. In addition, they are susceptible to repeated bouts of infection, and they have a 10-20 fold increased risk to develop leukemia. Neuropathological examination of the brain demonstrates decreased weight especially in the cerebellum and brain stem. Moreover, neuronal number is reduced in many regions of the brain. Magnetic imaging studies have shown that the frontal and temporal regions of the brain are proportionally diminished in DS, but the volumes of the subcortical nuclei are similar to those in control subjects. It has been known for a long time that there exists a disparity in the neuropsychological profile of children with DS. In comparison with children with mental retardation resulting from other etiologies, verbal short-term memory skills of children with DS are diminished. Conversely, visual-motor skills are comparatively well preserved. Scope This RFA focuses on cognition and behavior in individuals with DS. Applications may address one or more of the following topics: o Cognitive development and function; including learning and memory, language development, speech intelligibility, literacy development, motor development, social behavior and emotional development o Intervention strategies (behavioral, educational, pharmacological, nutritional, etc.) to improve cognitive development or to prevent cognitive decline and dementia or amelioration of maladaptive behaviors o Development of methodologies to assess effects of intervention o Assessment of the applicability of imaging, electrophysiology, pharmacology, molecular biology and behavior in following the developmental trajectories of different brain functions onto developing cognitive and motor skills o Characterization and evaluation of the cognitive, physiological, and molecular mechanisms of cognitive dysfunction o Examination of the mechanisms by which DS genetic status affects the development, function, and dysfunction of the nervous system, particularly with respect to cognition and behavior, including dementia o Development and use of animal models to evaluate the genetic, molecular, and physiological bases of cognitive dysfunction and to assess the potential clinical efficacy of therapeutic interventions INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research protocols involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 10.1- 43). All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and in the NIH Guide for Grants and Contracts, Volume 2 3, Number 11, March 18, 1994. For the purpose of this policy, clinical research is defined as human biomedical and behavioral studies of etiology, epidemiology, prevention (and prevention strategies), diagnosis, or treatment of diseases, disorders or conditions, including, but not limited to, clinical trials. LETTER OF INTENT Prospective applicants are asked to submit, by May 1, 1998, a letter of intent that includes a descriptive title of the proposed research, address, and telephone number of the Principal Investigator, names of other key personnel and, if applicable, participating institutions, and the number and title of the RFA in response to which the application may he submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains allows Institute staff to estimate the potential review workload and to avoid possible conflict of interest in the review. The letter of intent is to be sent to: Felix F. de la Cruz, M.D., M.P.H. Center for Research for Mothers and Children National Institute of Child Health and Human Development 6100 Executive Boulevard, Room 4B09, MSC 7510 Bethesda, MD 20892-7510 Telephone: (301) 496-1383 FAX: (301) 496-3791 Email: fd14a@NIH.GOV APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 5/95). Application kits are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda MD 20892-7910, telephone 301/710-0267, E-mail: ASKNIH@od.nih.gov; and from the program administrators listed under INQUIRIES. The RFA label available in the PHS 398 (rev. 5/95) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2 of the face page of the application form and the YES box must be marked. The applications must be prepared in a manner consistent with the instructions provided in PHS 398 (rev. 5/95) and, for small research grant applications assigned to NICHD, guidelines outlined in the NICHD Small Grants Program (NIH Guide, Volume 25, Number 3, February 9, 1996, PA-96-025) should be followed. Submit a signed, typewritten original of the application, including the Checklist, and three signed photocopies in one package to: CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DR, ROOM 1040 - MSC 7710 BETHESDA MD 20892-7710 BETHESDA MD 20817 (for express/courier service) At the time of submission, two additional copies of the application must be sent to: Scott F. Andres, Ph.D. Division of Scientific Review National Institute of Child Health and Human Development 6100 Executive Boulevard, Room 5E-03, MSC 7510 Bethesda, MD 20892-7510 Rockville, MD 20852 (for express/courier service) Telephone: (301) 496-1485 Applications must be received by June 11, 1998. If an application is received after this date, it will be returned to the applicant without review. The Center for Scientific Review (CSR) will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The CSR will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed for completeness by CSR and responsiveness by NICHD staff. Incomplete and/or non-responsive applications will be returned to the applicant without further consideration. Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by the NICHD Division of Scientific Review in accordance with the review criteria stated below. As part of the initial merit review, a process may be used by the initial review group in which applications will be determined to be competitive or non-competitive based on their scientific merit relative to other applications received in response to the RFA. Applications judged to be competitive will be discussed and assigned a priority score. Applications determined to be non- competitive will be withdrawn from further consideration, and the Principal Investigator and the official signing for the applicant organization will be notified. The second-level review will be made by the National Advisory Child Health and Human Development Council at its September 1998 meeting. The anticipated date of award is September 30, 1998. REVIEW CRITERIA The goals of NIH-supported research are to advance our understanding of biological systems, improve the control of disease, and enhance health. In the written review, comments on the following aspects of the application will be made in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in the assignment of the overall score. (1) Significance: Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field? (2) Approach: Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? (3) Innovation: Does the project employ novel concepts, approaches or method? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies? (4) Investigator: Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? (5) Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support? In addition to the above criteria, in accordance with NIH policy, all applications will also be reviewed with respect to the following: o The adequacy of plans to include both genders, minorities, and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated o The reasonableness of the proposed budget and duration in relation to the proposed research o The adequacy of the proposed protection for humans, animals or the environment, to the extent they may be adversely affected by the project proposed in the application AWARD CRITERIA In addition to the scientific and technical merit of the applications, other factors will be considered in making the awards. Among these are: o Relevance to mental retardation and its neurological origins o Access to unique populations o Institutional commitment and support INQUIRIES Written and telephone requests for the RFA, and the opportunity to clarify any issues or questions from the potential applicants are welcome. Inquiries regarding programmatic and scientific issues may be directed to; Felix F. de la Cruz, M.D., M.P.H. Center for Research for Mothers and Children National Institute of Child Health and Human Development 6100 Executive Boulevard, Room 4B-09 Bethesda, MD 20892 Telephone: (301) 496-1383 FAX: (301) 496-3791 Email: fd14a@NIH.GOV Sarah H. Broman, Ph.D. Division of Fundamental Neurosciences and Developmental Disorders National Institute of Neurological Disorders and Stroke 7550 Wisconsin Avenue, Room 8C06 Bethesda, MD 20892-9170 Telephone: (301) 496-5821 FAX: (301) 402-1501 Email: sb73f@nih.gov Direct inquiries regarding fiscal matters to: Mr. Edgar D. Shawver Grants Management Branch National Institute of Child Health and Human Development 6100 Executive Boulevard, Room 8 A-17 Bethesda, MD 20892 Telephone: (301) 496-1303 FAX: (301) 402-0915 E-mail: es65o@nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.865 Research for Mothers and Children. Awards are made under the authority of the Public Health Service Act, Title IV, Part A (Public Law 78-410 as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |